282 related articles for article (PubMed ID: 36623798)
1. Intravenous anakinra to curb cytokine storm in adult-onset Still's disease and in macrophage activation syndrome: A case series.
Bindoli S; Galozzi P; Doria A; Sfriso P
Joint Bone Spine; 2023 Mar; 90(2):105524. PubMed ID: 36623798
[TBL] [Abstract][Full Text] [Related]
2. Macrophage activation syndrome complicating adult onset Still's disease: A single center case series and comparison with literature.
Lenert A; Yao Q
Semin Arthritis Rheum; 2016 Jun; 45(6):711-6. PubMed ID: 26672682
[TBL] [Abstract][Full Text] [Related]
3. A comprehensive review on adult onset Still's disease.
Giacomelli R; Ruscitti P; Shoenfeld Y
J Autoimmun; 2018 Sep; 93():24-36. PubMed ID: 30077425
[TBL] [Abstract][Full Text] [Related]
4. Baseline clinical features predicting macrophage activation syndrome in patients with systemic adult-onset Still's disease receiving interleukin-6 inhibitor treatment.
Naniwa T; Yamabe T; Ohmura SI; Uehara K; Tamechika SY; Maeda S; Isogai S; Wada J
Int J Rheum Dis; 2022 Sep; 25(9):1003-1012. PubMed ID: 35719030
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of Interleukin-18 as a Diagnostic Biomarker to Differentiate Adult-Onset Still's Disease With/Without Macrophage Activation Syndrome From Other Secondary Hemophagocytic Lymphohistiocytosis in Adults.
Shiga T; Nozaki Y; Tomita D; Kishimoto K; Hirooka Y; Kinoshita K; Funauchi M; Matsumura I
Front Immunol; 2021; 12():750114. PubMed ID: 34691064
[TBL] [Abstract][Full Text] [Related]
6. [Clinical characteristics and diagnostic indicators of macrophage activation syndrome in patients with systemic lupus erythematosus and adult-onset Still's disease].
Yao HH; Yang F; Tang SM; Zhang X; He J; Jia Y
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Dec; 55(6):966-974. PubMed ID: 38101776
[TBL] [Abstract][Full Text] [Related]
7. Refractory adult-onset Still disease complicated by macrophage activation syndrome and acute myocarditis: A case report treated with high doses (8 mg/kg/d) of anakinra.
Parisi F; Paglionico A; Varriano V; Ferraccioli G; Gremese E
Medicine (Baltimore); 2017 Jun; 96(24):e6656. PubMed ID: 28614216
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics and comorbidities in adult-onset Still's disease using a large US administrative claims database.
Lenert A; Oh G; Ombrello MJ; Kim S
Rheumatology (Oxford); 2020 Jul; 59(7):1725-1733. PubMed ID: 31965185
[TBL] [Abstract][Full Text] [Related]
9. Persistent Pancytopenia as a Long-COVID Manifestation in a Patient with Adult-Onset Still's Disease: A Case Report.
Massimino M; Iaquinta FS; Naty S; Andreozzi F; Grembiale RD
Medicina (Kaunas); 2023 Jul; 59(7):. PubMed ID: 37512160
[No Abstract] [Full Text] [Related]
10. [Anakinra in refractory adult onset Still's disease].
Vercoutere W; Starmans-Kool M; Peeters RM
Ned Tijdschr Geneeskd; 2011; 155(18):A2966. PubMed ID: 21466723
[TBL] [Abstract][Full Text] [Related]
11. Hyperinflammation after anti-SARS-CoV-2 mRNA/DNA vaccines successfully treated with anakinra: Case series and literature review.
Bindoli S; Giollo A; Galozzi P; Doria A; Sfriso P
Exp Biol Med (Maywood); 2022 Feb; 247(4):338-344. PubMed ID: 35068221
[TBL] [Abstract][Full Text] [Related]
12. Adult-onset Still's disease in focus: Clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies.
Efthimiou P; Kontzias A; Hur P; Rodha K; Ramakrishna GS; Nakasato P
Semin Arthritis Rheum; 2021 Aug; 51(4):858-874. PubMed ID: 34175791
[TBL] [Abstract][Full Text] [Related]
13. Adult-onset Still's disease: Advances in the treatment.
Castañeda S; Blanco R; González-Gay MA
Best Pract Res Clin Rheumatol; 2016 Apr; 30(2):222-238. PubMed ID: 27886796
[TBL] [Abstract][Full Text] [Related]
14. Macrophage activation syndrome in patients with adult-onset Still's disease under tocilizumab treatment: A single-center observational study.
Yamabe T; Ohmura SI; Uehara K; Naniwa T
Mod Rheumatol; 2022 Jan; 32(1):169-176. PubMed ID: 33719871
[TBL] [Abstract][Full Text] [Related]
15. Anakinra in patients with treatment-resistant adult-onset Still's disease: four case reports with serial cytokine measurements and a review of the literature.
Kötter I; Wacker A; Koch S; Henes J; Richter C; Engel A; Günaydin I; Kanz L
Semin Arthritis Rheum; 2007 Dec; 37(3):189-97. PubMed ID: 17583775
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of macrophage activation syndrome complicating adult Still disease with anakinra.
Loh NK; Lucas M; Fernandez S; Prentice D
Intern Med J; 2012 Dec; 42(12):1358-62. PubMed ID: 23253002
[TBL] [Abstract][Full Text] [Related]
17. Prescribing motivations and patients' characteristics related to the use of biologic drugs in adult-onset Still's disease: analysis of a multicentre "real-life" cohort.
Ruscitti P; Cipriani P; Liakouli V; Iacono D; Pantano I; Caso F; Perosa F; Atzeni F; Cantatore FP; Scarpa R; Ciccia F; Giacomelli R
Rheumatol Int; 2020 Jan; 40(1):107-113. PubMed ID: 31263993
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of interstitial pneumonitis with anakinra in a patient with adult-onset Still's disease.
Sollano-Sancho I; Rubio-Cebrian B; de la Cruz ML; San-Jose-Montano B
Eur J Hosp Pharm; 2021 Nov; 28(6):346-349. PubMed ID: 32788403
[TBL] [Abstract][Full Text] [Related]
19. Neutrophil extracellular trap-induced intermediate monocytes trigger macrophage activation syndrome in adult-onset Still's disease.
Jia J; Wang M; Ma Y; Meng J; Zhu D; Chen X; Shi H; Sun Y; Liu H; Cheng X; Su Y; Ye J; Chi H; Liu T; Zhou Z; Wang F; Chen L; Yi D; Xiao Y; Yang C; Teng J; Hu Q
BMC Med; 2023 Dec; 21(1):507. PubMed ID: 38124139
[TBL] [Abstract][Full Text] [Related]
20. Successful outcome of two pregnancies in patients with adult-onset Still's disease treated with IL-1 receptor antagonist (anakinra).
Fischer-Betz R; Specker C; Schneider M
Clin Exp Rheumatol; 2011; 29(6):1021-3. PubMed ID: 22153586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
